Robert D. Leone
Johns Hopkins University · 84 works · 3,125 citations · h-index 14
Top works
- Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
- Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma
- Targeting adenosine for cancer immunotherapy
- Targeting metabolism to regulate immune responses in autoimmunity and cancer
- Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models
- Autophagy: a targetable linchpin of cancer cell metabolism
- Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug
- Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics
- Are aspen sterols and steryl esters changed structurally by kraft pulping and bleaching
- Introduction of a Novel HRP Substrate-Nanogold Probe for Signal Amplification in Immunocytochemistry
- Abstract 2329: Glutaminase inhibition with CB-839 enhances anti-tumor activity of PD-1 and PD-L1 antibodies by overcoming a metabolic checkpoint blocking T cell activation
- Metabolic Reprogramming of Tumor-Associated Macrophages Using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder Cancers
- Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy
- E-Cadherin Induces Serine Synthesis to Support Progression and Metastasis of Breast Cancer
- Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis
- QRICH1 mediates an intracellular checkpoint for CD8 + T cell activation via the CARD11 signalosome
- Why fungal growth is less effective in aspen heartwood than in aspen sapwood
- Abstract 2337: The adenosine A2A receptor antagonist CPI-444 blocks adenosine-mediated T-cell suppression and exhibits antitumor activity alone and in combination with anti-PD-1 and anti-PD-L1
- Abstract 4159: The COX-2/PGE2 pathway as a mediator of resistance to anti-PD-1 therapy
- Glutamine antagonist DRP-104 in combination with durvalumab in patients with advanced fibrolamellar carcinoma (FLC) following progression on prior anti-PD(L)1 therapy.